Invesco Ltd. Vaxart, Inc. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Vaxart, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 50,995 shares of VXRT stock, worth $42,835. This represents 0.0% of its overall portfolio holdings.

Number of Shares

50,995

Previous 48,171 5.86%

Holding current value

$42,835

Previous $32,000 34.38%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$0.58 - $0.99 $1,637 - $2,795	2,824 Added 5.86%	50,995 $43,000
Q2 2024 Aug 13, 2024	BUY	$0.53 - $1.3 $25,530 - $62,622	48,171 New	48,171 $32,000
Q3 2023 Nov 13, 2023	BUY	$0.69 - $0.85 $8,952 - $11,028	12,975 Added 47.58%	40,247 $30,000
Q2 2023 Aug 11, 2023	SELL	$0.6 - $1.41 $27,188 - $63,892	-45,314 Reduced 62.43%	27,272 $19,000
Q1 2023 May 12, 2023	BUY	$0.71 - $1.25 $10,204 - $17,966	14,373 Added 24.69%	72,586 $55,000
Q4 2022 Feb 13, 2023	BUY	$0.75 - $2.24 $9,336 - $27,883	12,448 Added 27.2%	58,213 $55,000
Q3 2022 Nov 14, 2022	BUY	$2.09 - $4.5 $2,522 - $5,431	1,207 Added 2.71%	45,765 $100,000
Q2 2022 Aug 15, 2022	SELL	$2.7 - $5.28 $15,948 - $31,188	-5,907 Reduced 11.71%	44,558 $156,000
Q1 2022 May 16, 2022	SELL	$4.29 - $6.64 $2,676 - $4,143	-624 Reduced 1.22%	50,465 $254,000
Q4 2021 Feb 14, 2022	SELL	$5.77 - $7.96 $104,085 - $143,590	-18,039 Reduced 26.1%	51,089 $321,000
Q3 2021 Nov 15, 2021	BUY	$6.67 - $9.8 $94,954 - $139,512	14,236 Added 25.93%	69,128 $549,000
Q2 2021 Aug 17, 2021	BUY	$5.06 - $10.78 $168,801 - $359,620	33,360 Added 154.93%	54,892 $411,000
Q1 2021 May 17, 2021	BUY	$5.64 - $23.33 $53,619 - $221,798	9,507 Added 79.06%	21,532 $130,000
Q4 2020 Feb 16, 2021	BUY	$3.5 - $7.98 $42,087 - $95,959	12,025 New	12,025 $68,000

Others Institutions Holding VXRT

# of Institutions

109

Shares Held

37.6M

Call Options Held

188K

Put Options Held

180K

View Full List

About Vaxart, Inc.

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $106M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

More about VXRT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account